Adimab turns profit on deals with GSK, Biogen
This article was originally published in Scrip
Executive Summary
Adimab signed its first-ever technology transfer and license agreement that gives a partner broad access to the Lebanon, New Hampshire-based company's antibody discovery platform with GlaxoSmithKline and immediately followed the first deal with a second, expanding Adimab's existing relationship with Biogen Idec.
You may also be interested in...
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.